This ATP-competitive c-MET inhibitor has been used by Avan and his colleagues [47] to demonstrate decreased tumor volume, prolonged survival, and increased blood and tissue concentrations of gemcitabine in orthotopic models of PC. The gene discussed is MET; the disease is neoplasm.